Comment on

• The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers.

  Han L, Diao L, Yu S, Xu X, Li J, Zhang R, Yang Y, Werner HMJ, Eterovic AK, Yuan Y, Li J, Nair N, Minelli R, Tsang YH, Cheung LWT, Jeong KJ, Roszik J, Ju Z, Woodman SE, Lu Y, Scott KL, Li JB, Mills GB, Liang H. Han L, et al. Cancer Cell. 2015 Oct 12;28(4):515-528. doi: 10.1016/j.ccell.2015.08.013. Epub 2015 Oct 1. Cancer Cell. 2015. PMID: 26439496 Free PMC article.
• Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome.

  Fumagalli D, Gacquer D, Rothé F, Lefort A, Libert F, Brown D, Kheddoumi N, Shlien A, Konopka T, Salgado R, Larsimont D, Polyak K, Willard-Gallo K, Desmedt C, Piccart M, Abramowicz M, Campbell PJ, Sotiriou C, Detours V. Fumagalli D, et al. Cell Rep. 2015 Oct 13;13(2):277-89. doi: 10.1016/j.celrep.2015.09.032. Epub 2015 Oct 1. Cell Rep. 2015. PMID: 26440892 Free PMC article.
• Elevated RNA Editing Activity Is a Major Contributor to Transcriptomic Diversity in Tumors.

  Paz-Yaacov N, Bazak L, Buchumenski I, Porath HT, Danan-Gotthold M, Knisbacher BA, Eisenberg E, Levanon EY. Paz-Yaacov N, et al. Cell Rep. 2015 Oct 13;13(2):267-76. doi: 10.1016/j.celrep.2015.08.080. Epub 2015 Oct 1. Cell Rep. 2015. PMID: 26440895